International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions
-
By
-
March 21, 2026
Objective:
To quantify and compare the completeness of instructions in product information documents (PIDs) for monitoring, preventing, and mitigating adverse drug reactions (ADRs) across selected countries.
Key Findings:
- Instructions for prevention and mitigation were complete in a median of only 30% of PIDs, highlighting a critical gap in patient safety.
- Monitoring instructions were complete in a median of 22% of PIDs, indicating a need for improvement.
- PIDs from the European Union and Canada had the highest availability of information, suggesting best practices.
- Disagreement in documentation of ADRs was noted, indicating a need for global collaboration to standardize information.
Interpretation:
The study highlights significant gaps in the completeness of ADR-related guidance in PIDs, suggesting that targeted improvements are necessary to enhance patient safety and therapeutic outcomes.
Limitations:
- The study focused only on selected countries, which may not represent global practices, limiting the generalizability of the findings.
- Potential biases in the selection of signals and PIDs could affect the findings, necessitating caution in interpretation.
Conclusion:
Enhancing the completeness of ADR guidance in PIDs through international collaboration, particularly in standardizing documentation practices, could improve the management of drug safety.
